Recent Data and New Learnings in Myeloproliferative Neoplasms

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.